SCHEMBL10243549

SCHEMBL10243549

CCN(CCNC(=O)OC)C(C)c1cnccc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
KMT2A Q03164 3/20 0.34
LMNA P02545 3/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA2 P47869 1/20 0.33
MAPK1 P28482 2/20 0.33
MTNR1A P48039 2/20 0.33
MTNR1B P49286 2/20 0.33
ADRA2A P08913 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243117 0.84 L3MBTL1 (0.41) KMT2AMEN1ALDH1A1NPSR1MTNR1A
SCHEMBL10244695 0.81 SMN1; SMN2 (0.41) LMNAALDH1A1SMN1; SMN2CYP3A4CYP2C19
SCHEMBL335194 0.79 CYP1A2 (0.39) CYP2C19ADRA2ACYP2D6CYP2C9
SCHEMBL10243156 0.79 ALDH1A1 (0.46) KMT2ALMNAMEN1ALDH1A1CYP3A4
SCHEMBL10243705 0.78 HCRTR1 (0.43) KMT2ALMNAMEN1SMN1; SMN2TSHR
SCHEMBL10243404 0.78 KDM4E (0.34) KMT2AMEN1MTNR1AMTNR1B
SCHEMBL10243135 0.78 APP (0.43) KMT2AMEN1
SCHEMBL10243634 0.77 TSHR (0.40) ALDH1A1CYP2C19MTNR1AMTNR1BADRA2A
SCHEMBL10243454 0.77 KDM4E (0.37) LMNAMAPK1ADRA2AKCNH2
SCHEMBL10243142 0.77 APP (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 TMEM97 4545/4885SIGMAR1 3998/4885KMT2A 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.